Novel HIV Antibody 007 Bypasses Viral Escape, Opens Vaccine Strategies
Researchers have discovered a novel broadly neutralizing antibody, 007, that targets the HIV-1 V3 glycan site in a glycan-independent manner, overcoming escape mechanisms. The antibody demonstrated robust neutralization of resistant viral strains, synergized with existing antibodies in humanized mice, and is now advancing preclinically with Vir Biotechnology. This breakthrough may guide next-generation vaccine strategies amid ongoing efforts to induce broadly neutralizing antibodies through novel immunogen designs.